Shares of Catalyst Pharmaceuticals Inc (NASDAQ:CPRX) reached a new 52-week high on Thursday . The stock traded as high as $4.31 and last traded at $4.20, with a volume of 67098 shares changing hands. The stock had previously closed at $4.02.
CPRX has been the topic of several research reports. Cantor Fitzgerald set a $8.00 price objective on Catalyst Pharmaceuticals and gave the company a “buy” rating in a research report on Wednesday, November 28th. BidaskClub cut Catalyst Pharmaceuticals from a “hold” rating to a “sell” rating in a research report on Wednesday, December 5th. HC Wainwright reissued a “buy” rating on shares of Catalyst Pharmaceuticals in a research report on Friday, December 14th. Piper Jaffray Companies boosted their price target on Catalyst Pharmaceuticals from $5.00 to $7.50 and gave the stock an “overweight” rating in a research report on Thursday, December 13th. Finally, Oppenheimer set a $6.00 price target on Catalyst Pharmaceuticals and gave the stock a “buy” rating in a research report on Thursday, November 29th. One investment analyst has rated the stock with a sell rating, one has issued a hold rating and five have assigned a buy rating to the stock. Catalyst Pharmaceuticals currently has an average rating of “Buy” and an average target price of $6.55.
The stock has a market capitalization of $413.02 million, a P/E ratio of -12.61 and a beta of 2.32.
Catalyst Pharmaceuticals (NASDAQ:CPRX) last issued its quarterly earnings results on Monday, March 18th. The biopharmaceutical company reported ($0.14) EPS for the quarter, missing analysts’ consensus estimates of ($0.12) by ($0.02). The firm had revenue of $0.50 million during the quarter. On average, equities research analysts expect that Catalyst Pharmaceuticals Inc will post -0.14 EPS for the current fiscal year.
In related news, Director Donald A. Denkhaus purchased 25,000 shares of the company’s stock in a transaction dated Thursday, December 27th. The shares were purchased at an average cost of $1.91 per share, with a total value of $47,750.00. Following the transaction, the director now directly owns 225,000 shares in the company, valued at approximately $429,750. The purchase was disclosed in a document filed with the SEC, which is available through this link. Insiders own 9.30% of the company’s stock.
Hedge funds have recently added to or reduced their stakes in the stock. Sofinnova Ventures Inc raised its stake in Catalyst Pharmaceuticals by 6.9% during the 3rd quarter. Sofinnova Ventures Inc now owns 1,549,552 shares of the biopharmaceutical company’s stock valued at $5,858,000 after buying an additional 99,595 shares during the last quarter. Teachers Advisors LLC boosted its holdings in shares of Catalyst Pharmaceuticals by 12.0% during the 3rd quarter. Teachers Advisors LLC now owns 218,143 shares of the biopharmaceutical company’s stock valued at $825,000 after purchasing an additional 23,321 shares during the last quarter. Vanguard Group Inc boosted its holdings in shares of Catalyst Pharmaceuticals by 4.3% during the 3rd quarter. Vanguard Group Inc now owns 4,458,151 shares of the biopharmaceutical company’s stock valued at $16,852,000 after purchasing an additional 185,017 shares during the last quarter. Dimensional Fund Advisors LP bought a new position in shares of Catalyst Pharmaceuticals during the 3rd quarter valued at about $990,000. Finally, JPMorgan Chase & Co. boosted its holdings in shares of Catalyst Pharmaceuticals by 9.6% during the 3rd quarter. JPMorgan Chase & Co. now owns 989,080 shares of the biopharmaceutical company’s stock valued at $3,739,000 after purchasing an additional 86,692 shares during the last quarter. 47.83% of the stock is currently owned by institutional investors and hedge funds.
ILLEGAL ACTIVITY WARNING: This report was published by Zolmax and is owned by of Zolmax. If you are reading this report on another publication, it was illegally copied and republished in violation of United States and international trademark & copyright legislation. The legal version of this report can be viewed at https://zolmax.com/investing/catalyst-pharmaceuticals-cprx-sets-new-12-month-high-at-4-31/2980486.html.
Catalyst Pharmaceuticals Company Profile (NASDAQ:CPRX)
Catalyst Pharmaceuticals, Inc, a biopharmaceutical company, focuses on developing and commercializing therapies for people with rare debilitating, chronic neuromuscular, and neurological diseases. Its product candidates include Firdapse, a proprietary form of amifampridine phosphate that has completed Phase III clinical trials for the treatment of patients with lambert-eaton myasthenic syndrome; is in Phase III clinical trial to treat congenital myasthenic syndromes; and is in Phase III clinical trial for the treatment of anti-MuSK antibody positive myasthenia gravis, as well as is in Phase II clinical trial for patients with spinal muscular atrophy type 3.
Featured Article: How is a Moving Average Calculated?
Receive News & Ratings for Catalyst Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Catalyst Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.